Page 105 - 51 the significance--29.2_opt

46. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination
therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Lancet 2009;373(9681):2125-35.
47. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM
Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to
prevent type 2 diabetes in a population with impaired glucose tolerance: rationale,
design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent
Diabetes Mellitus. Diabetes Care 1998;21(10):1720-5.
48. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial
intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J
Med 2003;348(5):383-93.
49. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the
UGDP. Am Heart J 1999;138(5 Pt 1):S346-52.
50. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and
death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71.
51. Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for
Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med 2010.
52. FDA. Systematic review of epidemiologic studies of cardiovascular risk in patients
treated with rosiglitazone or pioglitazone: FDA, 2010.
53. Rosen CJ. The rosiglitazone story − lessons from an FDA Advisory Committee meeting.
N Engl J Med 2007;357(9):844-6.
54. Merck. Update on Cardiovascular Outcomes Study with JANUVIA, 2010.
55. Takeda. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investiga-
tional Treatment for Type 2 Diabetes, 2010.
56. AstraZeneca. Bristol-Myers Squibb and AstraZeneca announce the commence-
ment of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients
with Diabetes Mellitus Trial (SAVOR-TIMI 53), 2010.
57. Clinical Trials.gov. The ORIGIN Trial (Outcome Reduction With Initial Glargine Inter-
vention), 2010.
58. Clinical Trials.gov. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus
Glimepiride in Patients With Type 2 Diabetes, 2010.
59. Clinical Trials.gov. BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes
Mellitus Patients., 2010.
60. Clinical Trials.gov. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL):
A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once
Weekly In Patients With Type 2 Diabetes Mellitus, 2010.
61. Clinical Trials.gov. Liraglutide Effect and Action in Diabetes: Evaluation of Cardio-
vascular Outcome Results - A Long Term Evaluation (LEADER™), 2010.
62. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al.
American Association of Clinical Endocrinologists medical guidelines for clinical
practice for the management of diabetes mellitus. Endocr Pract 2007;13 Suppl 1:1-68.
63. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor
agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;
368(9548):1696-705.
64. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3(3):153-65.
65. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/
dipeptidyl peptidase IV in cancer. Front Biosci 2008;13:1634-45.
66. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant
phenotype of prostate cancer cells by blocking basic fibroblast growth factor
signaling pathway. Cancer Res 2005;65(4):1325-34.
67. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppres-
sion of human non small cell lung carcinoma cells. Int J Cancer 2004;109(6):855-66.
68. Bristol-Myers Squibb Pharmaceuticals Ltd and AstraZeneca EEIG. Onglyza®
Summary of Product Characteristics. June, 2009.
69. Merck Sharpe & Dohme Ltd. Januvia® Summary of Product Characteristics. 2009.
70. Novartis Europharm Ltd. Galvus® Summary of Product Characteristics. 2009.
71. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide
effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in
patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;
24(1):275-86.

105